Summary: bioAffinity Technologies’ noninvasive lung cancer test, CyPath Lung, is available to Veterans and military personnel for early-stage lung cancer detection.
Takeaways:
- CyPath Lung, a noninvasive test for early-stage lung cancer, is now accessible to the Veterans Health Administration (VHA) and Military Health System, helping to improve lung cancer detection among high-risk Veterans.
- Veterans are 25% more likely to be diagnosed with lung cancer than non-Veterans, making early detection tools like CyPath Lung crucial for improving treatment outcomes.
- An economic study showed that incorporating CyPath Lung into standard care could save healthcare costs by reducing the need for invasive follow-up procedures and related complications.
BioAffinity Technologies, a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, announced that CyPath Lung, its noninvasive test to detect early-stage lung cancer, will be added to the U.S. Federal Supply Schedule, a procurement system that provides the Veterans Health Administration (VHA) and the Military Health System streamlined access to state-of-the-art healthcare products and services.
The Veterans Health Administration
The VHA, part of the U.S. Department of Veterans Affairs (VA), serves 9.1 million Veterans each year and is the largest integrated health care system in the country, providing care at 1,380 health care facilities, including 170 medical centers and 1,193 outpatient sites of care of varying complexity (VHA outpatient clinics). Approximately 8,000 Veterans are diagnosed and treated for lung cancer annually, according to the VA.
“Lung cancer is the leading cause of cancer-related death in Veterans, despite being one of the most preventable cancers in the world. The University of California, Irvine School of Medicine reports that an estimated 15 Veterans die of lung cancer each day, and Veterans are 25% more likely to receive a lung cancer diagnosis compared to non-Veterans,” bioAffinity President and CEO Maria Zannes says. “My father was one such Veteran who died from lung cancer at age 39. That is just one of many reasons I am immensely proud that VA and Department of Defense physicians will be able to order CyPath Lung for their patients to help detect early-stage lung cancer with the goal of leading to better treatment and longer lives.”
Retired Col. Roby Joyce, MD, medical director of bioAffinity’s subsidiary laboratory, Precision Pathology Laboratory Services, and a bioAffinity board member, served in the Army Medical Corps for 15 years.
“Both as a Veteran who was honored to serve and as the Medical Director for the lab that developed CyPath Lung to detect this deadly cancer, I am proud to partner with the VA and the Military Health System to help improve health outcomes for the millions of Veterans and active-duty military who are at higher risk for lung cancer,” Joyce says. “It’s incredibly gratifying to see the VA acknowledge CyPath Lung as a valuable tool for the early diagnosis of lung cancer, which affects far too many past and present members of our military.”
U.S. Veterans and Lung Cancer
Veterans are at higher risk for lung cancer due to older age, smoking, and environmental exposure during and after military service. Through programs like the Lung Precision Oncology Program (LPOP), the VA promotes annual lung cancer screening for high-risk individuals. CyPath Lung is especially effective for patients who receive a positive screening result. When a low dose computed tomography (LDCT) scan reveals indeterminate pulmonary nodules, CyPath Lung helps close the gap between a “wait and see” option and an invasive procedure, including biopsy, that may turn out to be unnecessary.
A recent economic impact study found that adding CyPath Lung to the current standard of care could save hundreds of millions of dollars per year in healthcare costs by reducing follow-up diagnostic assessments, expensive follow-up procedures and procedure-related complications.Â
Michael J. Morris, MD, Brooke Army Medical Center (BAMC) pulmonology and critical care physician and Assistant Dean of Research at San Antonio Uniformed Services Health Education Consortium (SAUSHEC), and Sheila A. Habib, MD, Director of the Pulmonary Lung Nodule Clinic and the Lung Cancer Screening Program at the South Texas Veterans Health Care Systems’ Audie L. Murphy Memorial Veterans Hospital and Assistant Professor at the University of Texas Health Science Center at San Antonio, were lead co-authors of the study.
Further reading: BioAffinity Automated Flow Cytometry Test Detects Lung Cancer in Sputum